NCT02522117 - Atorvastatin in the Recipient's Kidney Graft From a Living Donor | Biotech Hunter

Enrollment

48

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2018

Conditions

Renal Insufficiency

Interventions

DRUG

Atorvastatin

Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.

DRUG

Placebo

Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.

Trial Locations (1)

44340

Western Medical Center, Mexican Institute of Social Security, Guadalajara